Literature DB >> 19440116

Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients.

Mona Ben M'rad1, Stéphanie Leclerc-Mercier, Philippe Blanche, Nathalie Franck, Flore Rozenberg, Yvonne Fulla, Myriam Guesmi, Florence Rollot, Monique Dehoux, Loïc Guillevin, Laurence Moachon.   

Abstract

Drug-induced hypersensitivity syndrome (DIHS), also called drug rash with eosinophilia and systemic symptoms (DRESS), is a severe reaction usually characterized by fever, rash, and multiorgan failure, occurring 1-8 weeks after drug introduction. It is an immune-mediated reaction involving macrophage and T-lymphocyte activation and cytokine release, although no consensus has been reached as to its etiology. The skin, hematopoietic system, and liver are frequently involved. DIHS can mimic severe sepsis, viral infection, adult-onset Still disease (AOSD), or lymphoproliferation.We describe 24 consecutive patients with DIHS who were hospitalized between September 2004 and March 2008. Criteria for inclusion in this observational study were suspected drug reaction, eosinophilia >or=500/microL and/or atypical lymphocytes, involvement of at least 2 organs (skin being 1 of them), with suggestive chronology and exclusion of other diagnoses. Our cohort of 12 women and 12 men had a median age of 49 years (range, 22-82 yr), and 11 had skin phototype V or VI. Patients with mild or no rash were immunocompromised (7/24)- defined as treatment with prednisone (>or=10 mg/d) and another immunosuppressant drug, or human immunodeficiency virus infection. All patients were febrile (>38 degrees C), 14 had localized or generalized edema, 7 had pharyngitis, 8 had lymphadenopathy, 22 had hepatitis, 4 had nephritis, 2 had noninfectious and nonlithiasic angiocholitis or cholecystitis. Ten patients were hypotensive, 5 of whom had associated laboratory signs and/or imaging findings suggestive of acute myocardial dysfunction. Half of the patients had hemogram abnormalities, including eosinophilia. Nine DIHS patients fulfilled the Fautrel criteria for AOSD diagnosis, including glycosylated ferritin <20% in 4/11, with or without laboratory characteristics of hemophagocytosis. Twenty DIHS episodes occurred during the less sunny months of October to March.We determined 25-hydroxyvitamin D3 (25[OH]D3) levels in 18 patients and found that 9 patients had vitamin D deficiency (<25 nmol/L or <10 microg/L) and 5 had vitamin D insufficiency (25-50 nmol/L). Moreover, 25(OH)D3 levels were inversely correlated with ferritin values. After culprit-drug withdrawal, outcomes were favorable for all patients, including those with cardiac abnormalities under slow tapering of glucocorticoids.We recommend looking for the frequent but underdiagnosed hypersensitivity myocarditis with noninvasive diagnostic tools, such as N-terminal probrain natriuretic peptide, and promptly withdrawing the culprit drug and starting glucocorticoids. Vitamin D deficiency might be a DIHS risk or severity factor, especially for patients with high skin phototype and during the winter. Because DIHS clinical and laboratory patterns share similarities with AOSD and hemophagocytosis, DIHS should be included in their differential diagnoses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19440116     DOI: 10.1097/MD.0b013e3181a4d1a1

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  39 in total

1.  Ceftobiprole associated agranulocytosis after drug rash with eosinophilia and systemic symptoms induced by vancomycin and rifampicin.

Authors:  Thomas Wendland; Barbara Daubner; Werner J Pichler
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

2.  Duration of Treatment with Corticosteroids and Recovery of Kidney Function in Acute Interstitial Nephritis.

Authors:  Gema Fernandez-Juarez; Javier Villacorta Perez; Fernando Caravaca-Fontán; Luis Quintana; Amir Shabaka; Eva Rodriguez; Liliana Gadola; Alberto de Lorenzo; Maria Angeles Cobo; Aniana Oliet; Milagros Sierra; Carmen Cobelo; Elena Iglesias; Miguel Blasco; Cristina Galeano; Alfredo Cordon; Jesus Oliva; Manuel Praga
Journal:  Clin J Am Soc Nephrol       Date:  2018-11-05       Impact factor: 8.237

Review 3.  Multiple Drug Hypersensitivity.

Authors:  Werner J Pichler; Yuttana Srinoulprasert; James Yun; Oliver Hausmann
Journal:  Int Arch Allergy Immunol       Date:  2017-03-18       Impact factor: 2.749

Review 4.  Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings.

Authors:  Fumikazu Sakai; Takeshi Johkoh; Masahiko Kusumoto; Hiroaki Arakawa; Masahiro Takahashi
Journal:  Int J Clin Oncol       Date:  2012-11-10       Impact factor: 3.402

5.  A case of late kidney allograft failure: a clinical pathological conference from American Society of Nephrology Kidney Week 2011.

Authors:  Parmjeet Randhawa; Roslyn B Mannon
Journal:  Clin J Am Soc Nephrol       Date:  2012-08-02       Impact factor: 8.237

Review 6.  Hemophagocytic Syndrome and Critical Illness: New Insights into Diagnosis and Management.

Authors:  Zuzana Tothova; Nancy Berliner
Journal:  J Intensive Care Med       Date:  2014-01-08       Impact factor: 3.510

7.  Drug Reaction, Eosinophilia and Systemic Symptoms (DRESS) syndrome secondary to allopurinol with early lymphadenopathy and symptom relapse.

Authors:  Rhiannon Turney; Jordan Peter Skittrall; Joseph Donovan; Daniel Agranoff
Journal:  BMJ Case Rep       Date:  2015-10-05

Review 8.  Myocarditis.

Authors:  Sandeep Sagar; Peter P Liu; Leslie T Cooper
Journal:  Lancet       Date:  2011-12-18       Impact factor: 79.321

Review 9.  Hyperferritinemia and inflammation.

Authors:  Kate F Kernan; Joseph A Carcillo
Journal:  Int Immunol       Date:  2017-11-01       Impact factor: 4.823

10.  Drug associated vanishing bile duct syndrome combined with hemophagocytic lymphohistiocytosis.

Authors:  Hui Li; Xin Li; Xiao-Xing Liao; Hong Zhan; Yan Xiong; Chun-Lin Hu; Hong-Yan Wei; Xiao-Li Jing
Journal:  World J Gastrointest Endosc       Date:  2012-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.